**c-erbB-2/HER2**
Concentrated and Prediluted Rabbit Monoclonal Antibody
903-342-100419

<table>
<thead>
<tr>
<th>Catalog Number:</th>
<th>ACA 342 A, B</th>
<th>APA 342 AA</th>
<th>OAA 342 T60</th>
<th>VLTRZ 342 G20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description:</td>
<td>0.1, 0.5 mL, conc.</td>
<td>6.0 mL, RTU</td>
<td>60 tests, RTU</td>
<td>20 mL, RTU</td>
</tr>
<tr>
<td>Dilution:</td>
<td>1:50</td>
<td>Ready-to-use</td>
<td>Ready-to-use</td>
<td>Ready-to-use</td>
</tr>
<tr>
<td>Diluent:</td>
<td>Da Vinci Green</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Intended Use:**
Analyte Specific Reagent. Analytical and performance characteristics are not established.

**Summary & Explanation:**
Studies have shown this antibody recognizes a protein of 185 kDa, identified as the second member (cerbB-2/HER-2) of the c-erbB family. This rabbit monoclonal antibody is directed against the cytoplasmic domain of the human c-erbB-2 protein. The c-erbB-2 is closely related in structure to the epidermal growth factor receptor. Studies have shown the c-erbB-2 protein is over-expressed in a variety of carcinomas, especially those of breast and ovary. Immunohistochemical staining correlates with gene amplification. Studies have also shown that c-erbB-2 positive breast cancer usually correlates with negative staining for estrogen and progesterone receptors; thus a poorer predictive outcome is correlated with c-erbB-2 staining.

**Source:** Rabbit monoclonal
**Clone:** EP3 (previously known as EP1045Y)
**Isotype:** IgG

**Known Applications:**
Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

**Supplied As:**
Buffer with protein carrier and preservative

**Storage and Stability:**
Store at 2ºC to 8ºC. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date. Diluted reagents should be used promptly; any remaining reagent should be stored at 2ºC to 8ºC.

**References:**

Produced using Abcam’s RabMab® technology. RabMab® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.